# EDGAR Filing Document

**Accession Number:** 0001166834
**File Stem:** 0001178913-26-000276
**Filing Date:** 2026-2
**Character Count:** 13419
**Document Hash:** b5a64a91803a8e32bf1bfa2c8a29a1d1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-000276.hdr.sgml**: 20260202

**ACCESSION NUMBER**: 0001178913-26-000276

**CONFORMED SUBMISSION TYPE**: 15F-12B

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260202

**DATE AS OF CHANGE**: 20260202

**EFFECTIVENESS DATE**: 20260202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SHL TELEMEDICINE LTD
- **CENTRAL INDEX KEY:** 0001166834
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15F-12B
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41641
- **FILM NUMBER:** 26587543

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 90 YIGAL ALON STREET
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3
- **BUSINESS PHONE:** 972-3-5612212

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 90 YIGAL ALON STREET
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3

------

### UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 15F
**CERTIFICATION OF A FOREIGN PRIVATE ISSUER'S TERMINATION OF<br> REGISTRATION OF A CLASS OF SECURITIES UNDER SECTION 12(g) OF<br> THE SECURITIES EXCHANGE ACT OF 1934 OR ITS TERMINATION OF<br> THE DUTY TO FILE REPORTS UNDER SECTION 13(a) OR SECTION 15(d)<br> OF THE SECURITIES EXCHANGE ACT OF 1934**

#### Commission File Number: 001-41641

### SHL TELEMEDICINE LTD.
(Exact name of registrant as specified in its charter)

**90 Yigal Alon Street**<br> **Tel Aviv 67891, Israel**<br> **+972 (3) 561-2212**<br> (Address, including zip code, and telephone number, including area code, of registrant's principal<br> executive offices)

**Ordinary Shares, nominal value NIS 0.01 per share**<br> **American Depositary Shares, each representing one (1) ordinary share, nominal value NIS 0.01 per share**<br> (Title of each class of securities covered by this Form)

Place an X in the appropriate box(es) to indicate the provision(s) relied upon to terminate the duty to file reports under the Securities Exchange Act of 1934:

---

| | |
|:---|:---|
| Rule 12h-6(a) ☑ | Rule 12h-6(d) ☐ |
| (for equity securities) | (for successor registrants) |
| Rule 12h-6(c) ☐ | Rule 12h-6(i) ☐ |
| (for debt securities) | (for prior Form 15 filers) |

---

------

#### Part I

#### Item 1. Exchange Act Reporting History
A. SHL Telemedicine Ltd. (the "Company" or "Registrant") first incurred the duty to file reports under Section 13(a) or Section 15(d) of U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"), on
 March 30., 2023, the effective date of the Company's Registration Statement on Form 20-F (file no. 001-41641) (the "20-F Registration Statement") and Registration Statement on Form F-6 (file no. 333-270672), each filed with the Securities
 Exchange Commission (the "Commission") in connection with the listing of the Company's American Depositary Shares (the "ADSs"), each representing one (1) ordinary share, nominal value NIS 0.01 per share, of the Company (the "Ordinary
 Shares"), on the Nasdaq Capital Market ("Nasdaq").

B. The Registrant has filed all reports required under Section 13(a) or Section 15(d) of the Exchange Act and corresponding rules of the Commission for the 12 months preceding the filing of this Form 15F, including
 at least one Annual Report on Form 20-F pursuant to Section 13(a) of the Exchange Act.

#### Item 2. Recent United States Market Activity
The Registrant has never sold securities in the United States in a registered offering under the Securities Act of 1933, as amended (the "Securities Act").

#### Item 3. Foreign Listing and Primary Trading Market
A. The Registrant's Ordinary Shares are listed on the SIX Swiss Exchange Ltd. in Switzerland under the symbol SHLTN, which constitutes the primary market for the Registrant's Ordinary Shares. <br>

B. The Registrant's Ordinary Shares were first listed on the SIX Swiss Exchange on January 22, 2021. The Registrant's Ordinary Shares have been listed on the SIX Swiss Exchange for at least the 12 months preceding
 the filing of this Form 15F. <br>

C. During the 12-month period beginning January 1, 2025 and ending December 31, 2025, 85.8% of the average daily trading volume of the Registrant's Ordinary Shares on a worldwide basis (including Ordinary Shares
 previously represented by ADSs) occurred on the SIX Swiss Exchange, the primary trading market for the Registrant's Ordinary Shares listed above. The Registrant filed a Form 25 with the Commission on March 21, 2025 to delist its ADSs from
 Nasdaq. The last trading day of the ADSs on Nasdaq was March 28, 2025 and the delisting became effective on March 31, 2025. On March 18, 2025 the Registrant instructed The Bank of New York Mellon, as depositary of the Company's ADS program,
 to terminate the ADS program. The termination was effective on June 26, 2025.

#### Item 4. Comparative Trading Volume Data
Not applicable.

#### Item 5. Alternative Record Holder Information
As of January 15, 2026, the Registrant had 21 U.S. resident record holders of the Registrant's Ordinary Shares, the class of equity securities that are the subject of this Form 15F, including those Ordinary Shares previously represented by the Registrant's ADSs. The number of U.S. resident record holders the class of equity securities that are the subject of this Form 15F was calculated in accordance with Rule 12h-6(e) promulgated under the Exchange Act and based on the Registrant's shareholder register and a geographic survey conducted by Broadridge Financial Solutions, Inc.

#### Item 6. Debt Securities
Not applicable.

#### Item 7. Notice Requirement
A. The Registrant disclosed its intent to voluntarily terminate the registration of the securities that are the subject of this Form 15F in a Press Release, dated March 11, 2025 (the "March 2025 Press Release"), and
 a Press Release, dated February 2, 2026 (the "January 2026 Press Release"). <br>

B. Both the March 2025 Press Release and the January 2026 Press Release were disseminated by the major newswire service the Registrant typically uses to publish press releases and also published by various news
 services in the United States. In addition, both the March 2025 Press Release and the January 2026 Press Release were posted on the Registrant's website. The March 2025 Press Release was submitted to the Commission on a Report on Form 6-K
 via EDGAR on March 11, 2025 and the January 2026 Press Release is being filed with the Commission as Exhibit 99.1 attached hereto.

#### Item 8. Prior Form 15 Filers
Not applicable.

------

#### Part II

#### Item 9. Rule 12g3-2(b) Exemption
The Registrant intends to publish information in English, as required under Rule 12g3-2(b)(1)(iii), on its website at <u>www.shl-telemedicine.com</u>.

#### Part III

#### Item 10. Exhibits
<u>Exhibit</u> <u>Description</u> <br>[99.1](exhibit_99-1.htm) [Press Release, dated February 2, 2026](exhibit_99-1.htm)

#### Item 11. Undertakings
The undersigned issuer hereby undertakes to withdraw this Form 15F if, at any time before the effectiveness of its termination of reporting under Rule 12h-6, it has actual knowledge of information that causes it reasonably to believe that, at the time of filing the Form 15F:

(1) The average daily trading volume of its subject class of securities in the United States exceeded 5 percent of the average daily trading volume of that class of securities on a worldwide basis for the same recent
 12-month period that the issuer used for purposes of Rule 12h-6(a)(4)(i);<br>

(2) Its subject class of securities was held of record by 300 or more United States residents or 300 or more persons worldwide, if proceeding under Rule 12h-6(a)(4)(ii) or Rule 12h-6(c); or <br>

(3) It otherwise did not qualify for termination of its Exchange Act reporting obligations under Rule 12h-6.

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, SHL Telemedicine Ltd. has duly authorized the undersigned person to sign on its behalf this certification on Form 15F. In so doing, SHL Telemedicine Ltd. certifies that, as represented on this Form, it has complied with all of the conditions set forth in Rule 12h-6 for terminating its registration under section 12(g) of the Exchange Act, or its duty to file reports under section 13(a) or section 15(d) of the Exchange Act, or both.

---

| |
|:---|
| SHL TELEMEDICINE LTD. |
| <br> By: <u>/s/ Lior Haalman</u><br> Name: Lior Haalman<br> Title: Chief Financial Officer<br> Date: February 2, 2026 |

---

------

## Exhibit 99.1

------

<u>**Exhibit 99.1**</u>

![](image00001.jpg)

Press release

#### SHL files Form 15F to voluntarily terminate its SEC registration and reporting obligations
**TEL AVIV & ZURICH & NEW YORK, February 2, 2026** - SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN) ("**SHL**" or the "**Company**"), a leading provider and developer of advanced personal telemedicine solutions, announces that it is filing a Form 15F with the U.S. Securities and Exchange Commission (the "**SEC**") today to voluntarily terminate the registration of its ordinary shares under Section 12(g) of the U.S. Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), and its reporting obligations under Sections 13(a) and 15(d) of the Exchange Act. The Company is publishing this notice in accordance with Rule 12h-6(h) under the Exchange Act.

The Company previously terminated the trading of its American Depositary Receipts (ADRs) on the Nasdaq Capital Market in March 2025 and terminated the ADR program itself in June 2025. The Company has decided to seek deregistration at this time to reduce administrative costs and management time associated with SEC reporting (cf. ad hoc press release of the Company dated March 11, 2025).

Upon filing the Form 15F, SHL's reporting obligations under the Exchange Act, including the filing and submission of annual reports on Form 20-F and reports on Form 6-K, will be immediately suspended. The termination of the registration of the ordinary shares under the Exchange Act and of its reporting obligations thereunder is expected to become effective 90 days after the filing of the Form 15F if there are no objections from the SEC.

The Company's Ordinary Shares will continue to be listed on the SIX Swiss Exchange, which constitutes the Company's primary trading market. The Company remains current with its reporting requirements under the SIX Listing Rules and intends to publish information in English regarding the Company, including financial reports and press releases, on its website at <u>www.shl-telemedicine.com</u>, as required by Rule 12g3-2(b)(1)(iii) promulgated under the Exchange Act, in order to maintain the exemption provided by Rule 12g3-2(b) thereunder.

#### For further information, please contact:
Martina Müri, IRF, Phone: +41 43 244 81 41, mueri@irf-reputation.ch

#### About SHL Telemedicine:
SHL is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Valor: 1128957). For more information, please visit our web site at www.shl-telemedicine.com.

#### \*\*\*

#### Forward Looking Statements:
This announcement contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, specifically Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements, including statements regarding our intent, belief or current expectations, such as statements in this press release regarding our intention to file Form 15F, terminate our reporting obligations with the SEC and publish certain Company information in English on our website. Readers are cautioned that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from historical results or any future results expressed or implied by forward-looking statements. Factors that can cause actual results to differ from expectations and those contained in forward-looking statements include those risks described in Item 3.D. "Key Information—Risk Factors" contained in the Company's Registration Statement on Form 20-F filed with the U.S. Securities Exchange Commission (the "**SEC**") on May 15, 2025 and in its subsequent filings and submissions with the SEC. You should not place undue reliance on these forward-looking statements. All written and oral forward-looking statements, attributable to the Company, or persons acting on its behalf, are qualified in their entirety by these cautionary statements. Unless required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements.

------